J&J: Booster dose of its COVID shot prompts strong response

Johnson & Johnson's COVID-19 Vaccine Is 66% Effective in Global Trial.The single-shot vaccine was found to be 66% effective against moderate to severe illness in a global phase 3 trial.Against severe disease, the vaccine was 85% effective globally in adults of all ages and racial groups.In the United States, the vaccine was 72% effective against moderate and severe disease.Despite other vaccines being around 95% effective, experts say the Johnson & Johnson vaccine will still be useful.A vaccine that's inexpensive, that's a single dose, and that has no cold chain requirements — that's pretty good. , Dr. Anthony Fauci, via CNN.Johnson & Johnson is set to apply for emergency use authorization through the U.S. Food and Drug Administration next week, hoping for a late February rollout

LONDON — Johnson & Johnson released data showing that a booster dose to its one-shot coronavirus vaccine provides a strong immune response months after people receive a first dose.

J&J said in statement Tuesday that it ran two early studies in people previously given its vaccine and found that a second dose produced an increased antibody response in adults from ages 18 to 55. The study’s results haven’t yet been peer-reviewed.

“A booster dose of the Johnson & Johnson COVID-19 vaccine further increases antibody responses among study participants who had previously received our vaccine,” said Dr. Mathai Mammen, global head of research and development at J&J.

The company is in talks with regulators including the U.S. Food and Drug Administration, the European Medicines Agency and others regarding using booster doses of its vaccine.